Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay
Open Access
- 1 November 2011
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (11) , 1943-1950
Abstract
The Elecsys hepatitis B surface antigen (HBsAg) II quantitative assay is a new quantitative electrochemiluminescence immunoassay which uses onboard dilution and a simple algorithm to determine HBsAg levels expressed in international units (IU)/ml (standardized against the World Health Organization [WHO] Second International Standard). This study evaluated its performance using routine serum samples from a wide range of HBsAg carriers and patients with chronic hepatitis B (CHB). HBsAg levels were measured in serum samples collected independently by five centers in Europe, Australia, and Asia. Serial dilution analyses were performed to assess the recommended dilution algorithm and determine the assay range free of hook effect. Assay precision was also established. Following assessment of serial dilutions (1:100 to 1:1,000,000) of the 611 samples analyzed, 70.0% and 85.6% of samples tested with analyzers incorporating 1:100 (Elecsys 2010 and cobas e 411) and 1:400 (Modular Analytics E170) onboard dilution, respectively, fell within the linear range of the assay, providing a final result on the first test. No high-dose hook effect was seen up to the maximum HBsAg serum level tested (870,000 IU/ml) using the dilution algorithm. HBsAg levels were reliably determined across all hepatitis B virus (HBV) genotypes, phases of HBV infection, and stages of disease tested. Precision was high across all analyzers (% coefficient of variation [CV], 1.4 to 9.6; HBsAg concentrations, 0.1 to 37,300 IU/ml). The Elecsys HBsAg II quantitative assay accurately and reliably quantifies HBsAg in routine clinical samples. Onboard dilution minimizes retesting and reduces the potential for error.Keywords
This publication has 21 references indexed in Scilit:
- 69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTSJournal of Hepatology, 2011
- Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis BGastroenterology, 2011
- Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D CarriersGastroenterology, 2010
- A Longitudinal Study on the Natural History of Serum Hepatitis B Surface Antigen Changes in Chronic Hepatitis BHepatology, 2010
- A new role for an old marker, HBsAgJournal of Hepatology, 2010
- Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspectiveJournal of Hepatology, 2010
- Hepatitis B surface antigen seroclearance during chronic HBV infectionAntiviral Therapy, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †Hepatology, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009